Collectors Universe, Inc. (NASDAQ:CLCT), announced that its Board of Directors has approved an increase in its quarterly cash dividend to $0.35 per share per quarter, for an expected total annual cash dividend of $1.40 per common share. Collectors Universe Inc. (NASDAQ:CLCT) belongs to Services sector. Its net profit margin is 14.70% and weekly performance is 4.41%. On last trading day company shares ended up $22.27. Collectors Universe Inc. (NASDAQ:CLCT) distance from 50-day simple moving average (SMA50) is 3.76%.

Sportsman’s Warehouse Holdings, Inc. (NASDAQ:SPWH) announced that it participated in the 17th Annual ICR XChange Conference held at the JW Marriott Orlando Grande Lakes in Orlando, Florida. Management on Tuesday, January 13, 2015 at 1:30 p.m. Eastern Time. Sportsman’s Warehouse Holdings, Inc. (NASDAQ:SPWH) shares advanced 5.37% in last trading session and ended the day at $6.67. SPWH Gross Margin is 32.40% and its return on assets is 6.50%. Sportsman’s Warehouse Holdings, Inc. (NASDAQ:SPWH) quarterly performance is -6.58%.

TheStreet lowered shares of United Security Bancshares (NASDAQ:USBI) from a buy rating to a hold rating in a research report released on Monday morning. On 22 January, United Security Bancshares Inc. (NASDAQ:USBI) shares decreased -0.48% and was closed at $8.35. USBI EPS growth in last 5 year was -6.10%. United Security Bancshares Inc. (NASDAQ:USBI) year to date (YTD) performance is -5.54%.

On Jan 13, Dako, an Agilent Technologies Inc. (NYSE:A), announced that they have entered into a strategic partnership to supply antibodies for use in Dako-branded companion diagnostics products. Agilent Technologies Inc. (NYSE:A) ended the last trading day at $39.65. Company weekly volatility is calculated as 2.90% and price to cash ratio as 4.39. Agilent Technologies Inc. (NYSE:A) showed a weekly performance of 1.51%.

On Jan. 12, Pharmacyclics Inc. (NASDAQ:PCYC) provided its preliminary unaudited 2014 U.S. net product revenue results and 2015 U.S. net product revenue outlook at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. For the fiscal year ended December 31, 2014, U.S. net product revenue for IMBRUVICA® (ibrutinib) is expected to be approximately $492 million. Pharmacyclics Inc. (NASDAQ:PCYC) shares advanced 3.22% in last trading session and ended the day at $155.96. PCYC Gross Margin is 94.60% and its return on assets is 10.50%. Pharmacyclics Inc. (NASDAQ:PCYC) quarterly performance is 33.80%.